AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2022
Jul 28, 2022
30849_dirs_2022-07-28_a7637c19-7ae5-42a6-9d2e-2b259d47ca7f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2022-07-26
Reporting Person: Cramer Pamela J. (Chief Human Resources Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-07-26 | Common Stock | M | 3125 | — | Acquired | 3125 | Direct |
| 2022-07-27 | Common Stock | S | 901 | $11.68 | Disposed | 2224 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-07-26 | Restricted Stock Units | $ | M | 3125 | Acquired | Common Stock (3125) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
F3: The restricted stock units vest or have vested as to 25% of the total shares on each of July 26, 2022, July 26, 2023, July 26, 2024 and July 26, 2025. The restricted stock units have no expiration date.